Innate Pharma SA (IPHA)
2.20
+0.05
(+2.33%)
USD |
NASDAQ |
Sep 27, 16:00
2.19
-0.01
(-0.45%)
After-Hours: 20:00
Innate Pharma Research and Development Expense (Annual): 60.65M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 60.65M |
| December 31, 2022 | 54.48M |
| December 31, 2021 | 55.61M |
| December 31, 2020 | 56.77M |
| December 31, 2019 | 70.41M |
| Date | Value |
|---|---|
| December 31, 2018 | 82.13M |
| December 31, 2017 | 3.616M |
| December 31, 2016 | 53.82M |
| December 31, 2015 | 33.19M |
| December 31, 2014 | 30.15M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
54.48M
Minimum
2022
70.41M
Maximum
2019
59.59M
Average
56.77M
Median
2020
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 60.22M |
| Cellectis SA | 87.65M |
| Genfit SA | 50.57M |
| Inventiva SA | 119.10M |
| Nanobiotix SA | 41.57M |